A method and system to dry crack-free and high strength skin including an inorganic binder of an average particle size (D.sub.50) in a range between 10 nm and 700 nm on a porous ceramic body. The method includes supporting the honeycomb body on an end face such that axial channels and outer periphery are substantially vertical. A gas is flowed past the honeycomb body substantially parallel to the axial channel direction, substantially equally around the outer periphery of the skin, to uniformly dry the skin to form a partially dried skin under mild conditions. Then the partially dried skin may be dried more severely resulting in rapidly dried crack-free and high strength skin.

A method and system to dry crack-free and high strength skin including an inorganic binder of an average particle size (D.sub.50) in a range between 10 nm and 700 nm on a porous ceramic body. The method includes supporting the honeycomb body on an end face such that axial channels and outer periphery are substantially vertical. A gas is flowed past the honeycomb body substantially parallel to the axial channel direction, substantially equally around the outer periphery of the skin, to uniformly dry the skin to form a partially dried skin under mild conditions. Then the partially dried skin may be dried more severely resulting in rapidly dried crack-free and high strength skin.

The present invention relates to inorganic fibres having a composition comprising: 65.7 to 70.8 wt % SiO.sub.2; 27.0 to 34.2 wt % CaO; 0.10 to 2.0 wt % MgO; and optional other components providing the balance up to 100 wt %,
wherein the sum of SiO.sub.2 and CaO is greater than or equal to 97.8 wt %; and the other components, when present, comprise no more than 0.80 wt % Al.sub.2O.sub.3; and wherein the amount of MgO and other components are configured to inhibit the formation of surface crystallite grains upon heat treatment at 1100° C. for 24 hours, wherein said surface crystallite grains comprise an average crystallite size in a range of from 0.0 to 0.90 μm.

The present invention relates to inorganic fibres having a composition comprising: 65.7 to 70.8 wt % SiO.sub.2; 27.0 to 34.2 wt % CaO; 0.10 to 2.0 wt % MgO; and optional other components providing the balance up to 100 wt %,
wherein the sum of SiO.sub.2 and CaO is greater than or equal to 97.8 wt %; and the other components, when present, comprise no more than 0.80 wt % Al.sub.2O.sub.3; and wherein the amount of MgO and other components are configured to inhibit the formation of surface crystallite grains upon heat treatment at 1100° C. for 24 hours, wherein said surface crystallite grains comprise an average crystallite size in a range of from 0.0 to 0.90 μm.

Method and composition for producing aggregates from cement and concrete, including residual or returned concrete. Exemplary methods involve the use of an aggregate-forming inducer that provides a surface anchoring site for cement paste to bond/adhere, such as shredded news print, cardboard, or mixtures thereof, and also including fiber materials such as polymers, glass, and other material fibers. The aggregate-forming inducer is mixed with fresh concrete until aggregates are formed.

Method and composition for producing aggregates from cement and concrete, including residual or returned concrete. Exemplary methods involve the use of an aggregate-forming inducer that provides a surface anchoring site for cement paste to bond/adhere, such as shredded news print, cardboard, or mixtures thereof, and also including fiber materials such as polymers, glass, and other material fibers. The aggregate-forming inducer is mixed with fresh concrete until aggregates are formed.

The present invention relates to a composition of an intracanal medication agent for medicating root canals for a predetermined period of time. According to one aspect of the invention, there is provided an intracanal medication composition based on a calcium hydroxide component, comprising: calcium hydroxide or a calcium hydroxide producing component as a powder component; and at least one of diethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP) and diethylene glycol monoethyl ether (DEGEE) as a liquid component.

The present invention relates to a composition of an intracanal medication agent for medicating root canals for a predetermined period of time. According to one aspect of the invention, there is provided an intracanal medication composition based on a calcium hydroxide component, comprising: calcium hydroxide or a calcium hydroxide producing component as a powder component; and at least one of diethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP) and diethylene glycol monoethyl ether (DEGEE) as a liquid component.

The present invention relates to inorganic fibres having a composition comprising: 65.7 to 70.8 wt % SiO.sub.2; 27.0 to 34.2 wt % CaO; 0.10 to 2.0 wt % MgO; and optional other components providing the balance up to 100 wt %,
wherein the sum of SiO.sub.2 and CaO is greater than or equal to 97.8 wt %; and the other components, when present, comprise no more than 0.80 wt % Al.sub.2O.sub.3; and wherein the amount of MgO and other components are configured to inhibit the formation of surface crystallite grains upon heat treatment at 1100° C. for 24 hours, wherein said surface crystallite grains comprise an average crystallite size in a range of from 0.0 to 0.90 μm.

The present invention relates to inorganic fibres having a composition comprising: 65.7 to 70.8 wt % SiO.sub.2; 27.0 to 34.2 wt % CaO; 0.10 to 2.0 wt % MgO; and optional other components providing the balance up to 100 wt %,
wherein the sum of SiO.sub.2 and CaO is greater than or equal to 97.8 wt %; and the other components, when present, comprise no more than 0.80 wt % Al.sub.2O.sub.3; and wherein the amount of MgO and other components are configured to inhibit the formation of surface crystallite grains upon heat treatment at 1100° C. for 24 hours, wherein said surface crystallite grains comprise an average crystallite size in a range of from 0.0 to 0.90 μm.